triazoles has been researched along with sta 9090 in 112 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (0.89) | 29.6817 |
2010's | 99 (88.39) | 24.3611 |
2020's | 12 (10.71) | 2.80 |
Authors | Studies |
---|---|
Barsoum, J; Bear, M; Du, Z; Foley, KP; Lin, TY; London, C; Ying, W | 1 |
Baer, MR; Bansal, H; Bansal, S; Barsoum, J; Battiwalla, M; Blackman, RK; Foley, KP; Giles, FJ; Kelly, K; Lee, KP; Padmanabhan, S; Proia, DA; Rao, M; Sang, J; Swords, R; Tomlinson, GE; Ying, W | 1 |
Giaccone, G; Neckers, LM; Trepel, JB; Wang, Y | 1 |
Barsoum, J; Bates, RC; Blackman, RK; Foley, KP; Korbut, T; Koya, K; Liu, Y; Proia, DA; Rosenberg, AF; Sang, J; Smith, D; Zhou, D | 1 |
Barsoum, J; Bear, MD; Foley, KP; Inoue, T; London, CA; McCleese, J; Paalangara, R; Ying, W | 1 |
Acquaviva, J; Barsoum, J; Blackman, RK; Du, Z; Foley, KP; Inoue, T; Koya, K; Ogawa, LS; Proia, DA; Sang, J; Sun, L; Tatsuta, N; Wada, Y; Ye, S; Ying, W; Zhou, D | 1 |
Blackman, RK; Foley, KP; He, S; Koya, K; Liu, Y; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Ye, S; Zhang, C; Zhou, D | 1 |
Cicero, G; Gorska, M; Knap, N; Kuban-Jankowska, A; Popowska, U; Sawczuk, W; Sielicka-Dudzin, A; Wozniak, F | 1 |
Barsoum, J; Borgman, CL; Carey, CD; Carretero, J; Chen, L; Foley, KP; Inoue, T; Jimenez, JP; Li, D; Li, YC; Meyerson, M; Perera, SA; Rodig, SJ; Sang, J; Shapiro, GI; Shimamura, T; Sinha, P; Wong, KK; Ying, W | 1 |
Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Zhang, C | 1 |
Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Sequeira, M; Shafi, AA; Smith, DL; Wada, Y; Weigel, NL; Zhang, C | 1 |
Choi, HK; Lee, K | 1 |
Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, RB; Maris, JM; Reynolds, CP; Smith, MA | 1 |
Zhang, HJ; Zhang, L; Zhang, XT | 1 |
Hodi, FS; Marmarelis, ME; Wu, X | 1 |
Bullova, P; Giubellino, A; Landau, M; Lee, MJ; Neckers, L; Pacak, K; Scroggins, B; Sourbier, C; Trepel, JB; Ying, W | 1 |
Bradley, R; Chen, Y; El-Hariry, I; Goldman, JW; Gordon, GA; Guo, W; Inoue, T; Karol, MD; Raju, RN; Rosen, LS; Teofilivici, F; Vukovic, VM | 1 |
Acquaviva, J; Bates, RC; Camidge, DR; Doebele, RC; El-Hariry, I; Friedland, JC; He, S; Jiang, Q; Jimenez, JP; Lovly, CM; Morris, SW; Proia, DA; Sang, J; Sequeira, M; Shaw, AT; Smith, DL; Xue, L; Zhang, C | 1 |
Belani, CP; Bonomi, P; Brahmer, J; Chen, LC; El-Hariry, I; Goldman, J; Guo, W; Harper, H; Horn, L; Huberman, M; Koczywas, M; Paschold, E; Ramalingam, S; Salgia, R; Sandler, A; Sequist, LV; Shapiro, GI; Socinski, MA; Teofilovici, F; Vukovic, V; Webb, T; West, H; Wong, KK | 1 |
Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Smith, DL; Zhang, C | 1 |
Diaz, R; El-Hariry, I; El-Rayes, BF; Farris, AB; Ganji, PN; Landry, J; Mahaseth, H; Nagaraju, GP; Park, W; Proia, DA; Sullivan, PS; Taliaferro-Smith, L; Wen, J; Willingham, F | 1 |
Chrysikos, D; Dimopoulos, MA; Papadimitriou, CA; Psaltopoulou, T; Sergentanis, TN; Zagouri, F | 1 |
Astsaturov, I; Connolly, DC; Golemis, EA; Litwin, S; Liu, H; Maglaty, MA; Martin, LP; O'Brien, SW; Proia, DA; Serebriiskii, IG; Xiao, F | 1 |
Beebe, K; Huang, Y; Miyajima, N; Mollapour, M; Neckers, L; Nonomura, K; Rivas, C; Shinohara, N; Sourbier, C; Tatokoro, M; Trepel, JB; Tsutsumi, S; Yoshida, S | 1 |
Alberobello, AT; Giaccone, G; Lai, CH; Lee, DH; Park, KS; Petricoin Iii, EF; Pierobon, M; Pin, E; Raffeld, M; Wang, Y | 1 |
Acquaviva, J; Bates, RC; El-Hariry, I; He, S; Jimenez, JP; Nagai, M; Proia, DA; Sang, J; Sequeira, M; Shapiro, GI; Smith, DL; Spector, N; Tolaney, S; Zhang, C | 1 |
Chaturvedi, P; Gilkes, DM; Hu, H; Liang, H; Luo, W; Semenza, GL; Takano, N; Xiang, L | 1 |
Acquaviva, J; Bates, RC; He, S; Jimenez, JP; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Zhang, C | 1 |
Yaqub, F | 1 |
Pillai, RN; Ramalingam, SS | 1 |
Bauman, L; Chandarlapaty, S; D'Andrea, G; Drullinsky, P; El-Hariry, I; Fasano, J; Gilewski, T; Goldfarb, S; Haque, S; Hudis, C; Jhaveri, K; Lake, D; Lim, K; Modi, S; Moynahan, ME; Patil, S; Reddington, L; Robson, M; Sugarman, S; Vukovic, V; Wasserheit-Leiblich, C | 1 |
Acquaviva, J; Bates, RC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Zhang, C | 1 |
Bates, RC; Proia, DA | 1 |
Brennan, GT; Relias, V; Saif, MW | 1 |
Jang, SW; Kim, J; Ko, J; Oh, M; Park, E; Park, S | 1 |
Bates, RC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL | 1 |
Acquaviva, J; Bates, RC; He, S; Inoue, T; Jimenez, JP; Knowles, MA; Nagai, M; Ogawa, LS; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Tatsuta, N; Zhang, C | 1 |
Ebi, H; Kita, K; Matsumoto, K; Nanjo, S; Takeuchi, S; Tanimoto, A; Yamada, T; Yano, S | 1 |
Acquaviva, J; Bates, RC; Jimenez, JP; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Zhang, C | 1 |
Bogush, I; Cai, KQ; Efimov, A; Egleston, BL; Golemis, EA; Hensley, HH; Klein-Szanto, A; Nikonova, AS; Plotnikova, OV; Seeger-Nukpezah, T; Serzhanova, V | 1 |
Chen, ZG; Diaz, R; Liu, Y; Magliocca, K; Muller, S; Patel, K; Saba, N; Wen, J | 1 |
Beißbarth, T; Dobbelstein, M; Gaedcke, J; Ghadimi, M; Grade, M; He, S; Kramer, F; Landmann, H; Moll, U; Ogawa, LS; Proia, DA | 1 |
Abrams, TA; Blaszkowsky, LS; Chen, J; Goyal, L; Karol, MD; McCleary, NJ; Sheehan, S; Sundaram, E; Wadlow, RC; Wolpin, BM; Zhu, AX | 1 |
Alese, OB; Diaz, R; El-Rayes, BF; Landry, J; Nagaraju, GP | 1 |
Capanu, M; Cercek, A; Chou, JF; Gollub, M; Proia, DA; Raasch, P; Reidy-Lagunes, D; Saltz, LB; Shia, J; Solit, DB; Vakiani, E | 1 |
Chen, K; Hua, Y; Lian, C; Liang, Z; Liu, H; Lu, J; Ruan, L; Shi, H; Tu, Z; Zhang, P | 1 |
Anderson, GP; Asselin-Labat, ML; Bozinovski, S; Burns, CJ; Donald, A; Dousha, L; Lilja, A; McArthur, K; Nguyen, T; Vlahos, R; Weeden, CE; Wong, ZX | 1 |
Burnett, AK; Hills, R; Lazenby, M; Zabkiewicz, J | 1 |
Bates, RC; Chu, J; Huang, Q; Inoue, T; Liu, Y; Rao, PE; Shin Ogawa, L; Sonderfan, AJ; Ye, J; Ying, W; Zhou, D | 1 |
Andric, Z; Bondarenko, I; Ceric, T; Ciuleanu, T; Felip, E; Fennell, D; Goss, G; Hirsh, V; Khuri, F; Komov, D; Ramalingam, S; Rosell, R; Salgia, R; Samarzija, M; Schmid-Bindert, G; Shapiro, G; Sheldon, E; Spicer, J; Teofilovici, F; Vukovic, V; Wehler, T; Zaric, B | 1 |
Alexandrova, EM; Dobbelstein, M; Li, D; Lozano, G; Moll, UM; Proia, DA; Schulz, R; Xu, S; Yallowitz, AR | 1 |
Seo, YH | 1 |
Hagiwara, M; Hosoya, T; Kato-Sumida, T; Kii, I; Koike, Y; Okuno, Y; Sonamoto, R; Sumida, Y | 1 |
Acquaviva, J; Astsaturov, I; Bates, RC; Chimmanamada, D; He, S; Inoue, T; Jimenez, JP; Khazak, V; Ogawa, LS; Osman, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Tatsuta, N; Ying, W; Zhang, C; Zhang, J | 1 |
Epperly, MW; Gomez-Casal, R; Greenberger, JS; Levina, V; Proia, DA; Wang, H | 1 |
Alarcon, S; Beebe, K; Khamit-Kush, K; Kijima, T; Lee, S; Neckers, L; Prince, TL; Rivas, C; Schwartz, H; Scroggins, BT; Tatokoro, M; Trepel, JB; Tsutsumi, S; Yim, K | 1 |
Cavanaugh, A; Danella, JF; Juengst, B; Sheridan, K; Williams, H | 1 |
Antonarakis, ES; Dzinic, SH; Freeman, S; Heath, EI; Heilbrun, LK; Li, X; Liu, G; Sheng, S; Smith, D; Stein, M; Thakur, MK; Vaishampayan, U | 1 |
El-Rayes, BF; Landry, J; Mezina, A; Nagaraju, GP; Shaib, WL | 1 |
Agyeman, AS; Conzen, SD; Jun, WJ; Kim, CR; Kocherginsky, M; Proia, DA; Skor, MN | 1 |
Anders, RA; Annadanam, A; Ballew, M; Belcaid, Z; Cades, JA; Chettiar, ST; Herman, JM; Kato, Y; Lim, M; Malek, R; Manmiller, S; Nugent, KM; Proia, D; Taparra, K; Tran, PT; Wang, H | 1 |
Diao, L; Komaki, R; Lin, SH; Liu, H; Potter, A; Proia, DA; Qiao, Y; Tailor, R; Wang, J; Wang, Y; Zhang, J | 1 |
Ali, MA; Chavez, M; Cohen, JI; Dowdell, K; El-Hariry, I; Lee, MJ; Proia, DA; Shatzer, A; Tomita, Y; Trepel, JB | 1 |
Bastians, H; Concin, N; Dobbelstein, M; Edmunds, S; Erytch, N; Kramer, D; Moll, UM; Roßmann, L; Schulz-Heddergott, R; Stark, N | 1 |
Alturkmani, H; Baltezor, M; Butte, AJ; Chen, B; Flynn, CA; Godwin, AK; Hyter, S; Ma, Y; Neville, KA; Pessetto, ZY; Rosenthal, HG; Weir, SJ | 1 |
Giaccone, G; Subramaniam, DS; Warner, EA | 1 |
Bullinger, L; Döhner, H; Fröhling, S; Grasedieck, S; Kuchenbauer, F; Miller, C; Reinhart, S; Rouhi, A; Scholl, C; Stolze, B | 1 |
Abe, R; Amoh, Y; Fukushima, S; Hoshina, D; Ihn, H; Jinnin, M; Kajihara, I; Masuzawa, M; Yamada-Kanazawa, S | 1 |
Banerjee, T; Heckert, B; Kallu, J; Naz, S; Santra, S; Shelby, T; Sulthana, S; Vuppala, SR; Yambem, O | 1 |
Fu, L; Gu, Y; Jiang, J; Li, L; Li, Z; Liu, J; Lu, Y; Niu, D; Xia, F; Xu, W; Zhou, Z | 1 |
Agarwal, PK; Hammerich, KH; Hao, JJ; Krane, LS; Li, QQ; Neckers, L; Sanford, T; Trepel, JB; Zhang, Z | 1 |
Alexandrova, EM; Moll, UM; Xu, S | 1 |
Ayers, GD; Berlin, JD; Cardin, DB; Chan, E; Goff, LW; Jones, CM; Thota, R; Whisenant, JG | 1 |
Chen, MH; Chou, TC; Hsueh, C; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN | 1 |
Chen, Z; El-Rayes, BF; Lesinski, GB; Merchant, N; Nagaraju, GP; Wu, C | 1 |
Lee, H; Parris, AB; Saini, N; Yang, X; Zhao, M | 1 |
Abu Jhaisha, S; Becker, W; Kii, I; Knapp, S; Papadopoulos, C; Sonamoto, R; Widowati, EW | 1 |
Allison, JP; Amaria, R; Ashkin, E; Davis, RE; Devi, S; Hanash, SM; Heffernan, T; Huang, L; Hwu, P; Khong, H; Kuiatse, I; Liu, C; Lizee, G; Malu, S; Mbofung, RM; McKenzie, JA; Muller, FL; Peng, W; Proia, D; Roszik, J; Satani, N; Talukder, AH; Tieu, T; Tripathi, SC; Williams, L; Xu, C; Zhang, M | 1 |
Alessandrini, G; Amoreo, CA; Blandino, G; Ciliberto, G; Cioce, M; De Maria, R; di Martino, S; Facciolo, F; Galati, R; Nuvoli, B; Pass, HI; Strano, S | 1 |
Deneka, AY; Gaponova, A; Golemis, EA; Hensley, HH; Kiseleva, AA; Kopp, MC; Korobeynikov, V; Nikonova, AS; Proia, DA; Seeger-Nukpezah, TN; Serebriiskii, IG; Somlo, S | 1 |
Fang, T; Lv, C; Nagle, DG; Wang, JX; Wu, T; Yang, PM; Yuan, X; Zeng, HW; Zhang, C; Zhang, WD; Zhou, YD | 1 |
Burns, TF; Chatterjee, S; Goldstein, LA; Han, J; Hou, W; Rabinowich, H | 1 |
Huang, L; Huang, Y; Huang, Z; Jiang, Y; Liao, Y; Shen, Y; Sun, X; Wei, G; Xu, X; Zhao, C | 1 |
Chen, AP; Do, K; Doroshow, JH; Juwara, L; Kummar, S; Meehan, R; O'Sullivan Coyne, G; Rubinstein, L; Zlott, J | 1 |
Alemà, S; Amoreo, CA; Anastasi, S; Borad, MJ; Buglioni, S; Castellani, L; Cristinziano, G; Egan, JB; Lamberti, D; Leonetti, C; Porru, M; Segatto, O; Shi, CX | 1 |
Acquaviva, J; Bear, MD; Bechtel, SA; Bernabe, LF; Gardner, HL; London, CA; Ogawa, LS; Proia, DA; Sequeira, M; Smith, DL | 1 |
Buchbinder, EL; Chen, T; Flaherty, KT; Giobbie-Hurder, A; Hodi, FS; Ibrahim, N; Jacene, HA; Lawrence, DP; Luke, JJ; McDermott, DF; Ott, PA; Shah, S; Sullivan, RJ | 1 |
He, GL; Li, P; Luo, X; Luo, Z; Shen, TT; Yang, J; Yang, XS | 1 |
Huang, LJ; Peng, Y; Peng, YC; Wang, S; Wang, XL; Zhang, Y | 1 |
Abbey, YC; Agarwal, S; Alilin, AN; Beshiri, ML; Cawley, J; Corey, E; Fang, L; Fuller, C; Guha, R; Hoover, S; Hynes, PG; Jansson, KH; Kelly, K; Klummp-Thomas, C; Lake, R; McKnight, C; Nguyen, HM; Proia, DA; Simmons, JK; Simpson, RM; Stahl, LE; Thomas, CJ; Tice, CM; Tucker, JB; Yin, J; Zhang, X | 1 |
Chang, DJ; Kang, J; Kim, H; More, KN; Park, JH; Taş, İ; Young Lee, J | 1 |
Cahill, FF; Drobnitzky, N; Jiang, Y; Kong, A; Lourenco, LM; Mumin, NH; Patel, A; Ryan, AJ | 1 |
Brown, LE; Chatterjee, S; Collins, C; Cowen, LE; Huang, DS; Hui, R; Hutchinson, A; Krysan, DJ; LeBlanc, EV; Lindquist, S; McLellan, CA; Nation, CS; Pizarro, J; Porco, JA; Robbins, N; Shekhar-Guturja, T; Tatu, U; Trilles, R; Whitesell, L; Xie, JL | 1 |
Almobarak, B; Altiparmak, G; Arvidsson, Y; Elf, AK; Elias, E; Forssell-Aronsson, E; Hofving, T; Johanson, V; Kristiansson, E; Nilsson, O; Sandblom, V; Shubbar, E; Swanpalmer, J | 1 |
El-Rayes, BF; Landry, JC; Lesinski, GB; Nagaraju, GP; Shaib, WL; Zakka, KM | 1 |
Banerjee, T; Darji, S; Fletcher, C; Gerasimchuk, NN; Higginbotham, R; Kallu, J; Santra, S; Sulthana, S | 1 |
Kurihara, E; Namba, K; Ogoshi, Y; Okazaki, M; Sato, H; Shien, K; Shien, T; Soh, J; Suzawa, K; Takahashi, Y; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Yamamoto, H; Yoshioka, T | 1 |
Chen, X; Dai, X; Li, L; Miao, W; Wang, Y; Zhao, Y | 1 |
Li, L; Miao, W; Wang, Y | 1 |
Dou, JP; Liang, P; Liu, FY; Yu, J; Zhai, HY; Zhou, QF; Zhu, XY | 1 |
Abrams, TA; Allen, JN; Carpenter, AN; Chan, JA; Chaudhary, SP; Clark, JW; Enzinger, PC; Goessling, W; Goyal, L; Heist, R; Kwak, EL; McCleary, NJ; Ng, K; Ryan, DP; Schrag, D; Wadlow, RC; Wolpin, BM | 1 |
Addi, L; Alfano, L; Baldassarre, G; Bruzzese, F; Budillon, A; Capone, F; Costa, A; Di Gennaro, E; Iannelli, F; Lombardi, R; Milone, MR; Moccia, T; Pucci, B; Roca, MS; Sonego, M | 1 |
Hayashi, K; Onda, T; Onidani, K; Sekikawa, S; Shibahara, T; Shiraishi, N; Watanabe, K | 1 |
Alexandrova, EM; Eyermann, CE; Haley, JD | 1 |
Özgür, A | 1 |
Banerjee, T; Gross, RA; Naz, S; Santra, S; Totsingan, F; Woody, K | 1 |
Eshleman, JR; Gulla, A; Kazlauskas, E; Liang, H; Matulis, D; Petrauskas, V; Strupas, K | 1 |
Al-Lazikani, B; Antolin, AA; Clarke, PA; Collins, I; Workman, P | 1 |
Golemis, EA; Liu, H; Liu, L; Lu, Z; Shi, X; Tu, Z; Zhang, P | 1 |
Deycmar, S; Georg, D; Kerschbaum-Gruber, S; Mara, E; Pruschy, M; Waller, V | 1 |
Abd-Eldayem, MA; Cavalu, S; Hasan, AM; Saber, S; Yahya, G; Youssef, ME | 1 |
10 review(s) available for triazoles and sta 9090
Article | Year |
---|---|
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Evaluation, Preclinical; HSP90 Heat-Shock Proteins; Humans; Mice; Neoplasms; Structure-Activity Relationship; Triazoles | 2010 |
Geldanamycin and its derivatives as Hsp90 inhibitors.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Cyclin-Dependent Kinases; HSP90 Heat-Shock Proteins; Humans; Indoles; Lactams, Macrocyclic; Macrolides; Models, Biological; Mutation; Novobiocin; Proto-Oncogene Proteins c-raf; src-Family Kinases; Transforming Growth Factor beta; Triazoles; Tumor Suppressor Protein p53 | 2012 |
Recent updates on the development of ganetespib as a Hsp90 inhibitor.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Clinical Trials as Topic; Drug Design; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Protein Folding; Triazoles | 2012 |
[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
Topics: Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Triazoles | 2012 |
Hsp90 inhibitors in breast cancer: a systematic review.
Topics: Adenine; Antineoplastic Agents; Benzamides; Benzoquinones; Biomarkers, Tumor; Female; Glycine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Indazoles; Isoxazoles; Lactams, Macrocyclic; Pyridines; Resorcinols; Triazoles; Triple Negative Breast Neoplasms | 2013 |
Heat shock protein 90 inhibitors in non-small-cell lung cancer.
Topics: Benzamides; Benzoquinones; Carcinoma, Non-Small-Cell Lung; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Isoxazoles; Lactams, Macrocyclic; Lung Neoplasms; Molecular Targeted Therapy; Resorcinols; Treatment Outcome; Triazoles | 2014 |
Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Triazoles | 2014 |
Organelle-specific Hsp90 inhibitors.
Topics: Animals; Benzoquinones; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Organelles; Triazoles | 2015 |
Ganetespib for small cell lung cancer.
Topics: Animals; Antineoplastic Agents; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Molecular Weight; Small Cell Lung Carcinoma; Triazoles; Up-Regulation | 2017 |
Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Triazoles | 2023 |
13 trial(s) available for triazoles and sta 9090
Article | Year |
---|---|
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; HSP90 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Treatment Outcome; Triazoles | 2013 |
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Topics: Adult; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays; Young Adult | 2013 |
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Genotype; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Triazoles | 2013 |
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; HSP90 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Triazoles | 2014 |
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; HSP90 Heat-Shock Proteins; Humans; Liver; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Treatment Outcome; Triazoles | 2015 |
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Survival Rate; Triazoles | 2014 |
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; HSP90 Heat-Shock Proteins; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Taxoids; Treatment Outcome; Triazoles | 2015 |
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; HSP90 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Triazoles | 2016 |
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Triazoles | 2018 |
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sarcoma; Triazoles | 2018 |
Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Dogs; HSP90 Heat-Shock Proteins; Leukemia, Mast-Cell; Mice; Oncogenes; Proteolysis; Proto-Oncogene Proteins c-kit; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; HSP90 Heat-Shock Proteins; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazoles; Uveal Neoplasms | 2018 |
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; HSP90 Heat-Shock Proteins; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome; Triazoles | 2020 |
89 other study(ies) available for triazoles and sta 9090
Article | Year |
---|---|
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Primers; Dog Diseases; Dogs; HSP90 Heat-Shock Proteins; Leukemia, Mast-Cell; Mastocytoma; Mice; Mice, SCID; Proto-Oncogene Proteins c-kit; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Triazoles | 2008 |
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoquinones; Cell Line, Tumor; Etoposide; Female; Gene Expression Regulation, Leukemic; Gene Silencing; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid; Mice; Mice, SCID; Proteasome Endopeptidase Complex; Protein Interaction Domains and Motifs; Protein Structure, Tertiary; Triazoles; WT1 Proteins | 2010 |
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.
Topics: Animals; Cell Division; Genes, cdc; HSP90 Heat-Shock Proteins; Janus Kinase 2; Mice; Neoplasms, Experimental; Signal Transduction; STAT Transcription Factors; Triazoles; Tumor Cells, Cultured | 2011 |
Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dogs; Female; HSP90 Heat-Shock Proteins; Indoles; Male; Neoplasms; Prodrugs; Tandem Mass Spectrometry; Triazoles | 2011 |
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemical and Drug Induced Liver Injury; Crystallography, X-Ray; Female; Heart; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; K562 Cells; Lactams, Macrocyclic; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms; Rabbits; Rats; Rats, Sprague-Dawley; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Paclitaxel; Taxoids; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Intramolecular Oxidoreductases; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, SCID; Prostaglandin-E Synthases; Protein Binding; Protein Stability; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, ras; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mutation; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
Topics: Animals; Apoptosis; Benzoquinones; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Flow Cytometry; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Mice; Mice, SCID; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; GTP Phosphohydrolases; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Inhibitory Concentration 50; Melanoma; Membrane Proteins; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Skin Neoplasms; Triazoles | 2013 |
Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Animals; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Pheochromocytoma; Rats; Triazoles | 2013 |
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; HSP90 Heat-Shock Proteins; Humans; Inflammation; Mice, SCID; Molecular Targeted Therapy; Protein Stability; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Collagen; Colorectal Neoplasms; Down-Regulation; Drug Combinations; Female; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Laminin; Mice, Nude; Platelet-Derived Growth Factor; Proteoglycans; Rectal Neoplasms; Ribonuclease, Pancreatic; RNA, Messenger; Specific Pathogen-Free Organisms; STAT3 Transcription Factor; Transforming Growth Factor beta1; Triazoles; Vascular Endothelial Growth Factor A; Vesicular Transport Proteins; Xenograft Model Antitumor Assays | 2013 |
Ganetespib AIDS lung cancer survival.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Flow Cytometry; Gene Regulatory Networks; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Protein Array Analysis; RNA, Small Interfering; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cells, Cultured; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Female; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Neoplasms; NIH 3T3 Cells; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Triazoles; Xenograft Model Antitumor Assays | 2013 |
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Synergism; G2 Phase Cell Cycle Checkpoints; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Small Cell Lung Carcinoma; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mitosis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1; Immunoblotting; Immunohistochemistry; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neovascularization, Pathologic; Neural Cell Adhesion Molecule L1; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Triple Negative Breast Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; HSP90 Heat-Shock Proteins; Humans; Indoles; Melanoma; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sulfonamides; Triazoles; Vemurafenib; Xenograft Model Antitumor Assays | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Heat-Shock Response; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Random Allocation; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Novel agents for the treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Cancer Vaccines; Drug Therapy; HSP90 Heat-Shock Proteins; Humans; Immunologic Factors; Immunotherapy; Mucin 5AC; Pancreatic Neoplasms; Treatment Outcome; Triazoles | 2014 |
The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis.
Topics: Animals; Aorta; Atherosclerosis; Benzoquinones; Cell Cycle Checkpoints; Cell Line; Cell Movement; Cell Proliferation; Cholesterol; Diet, High-Fat; Gene Expression Regulation; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Plaque, Atherosclerotic; Primary Cell Culture; Receptors, LDL; Signal Transduction; Triazoles | 2014 |
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Female; Fluorouracil; HCT116 Cells; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Radiation-Sensitizing Agents; Radiation, Ionizing; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2014 |
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Topics: Animals; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Random Allocation; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Triazoles; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
Topics: Benzoquinones; Blotting, Western; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Hepatocyte Growth Factor; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Ligands; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Transforming Growth Factor alpha; Triazoles | 2014 |
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice, SCID; Mutation; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Nedd9 restrains renal cystogenesis in Pkd1-/- mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Aurora Kinase A; Calcium Signaling; Cilia; Disease Models, Animal; Epithelial Cells; Female; HSP90 Heat-Shock Proteins; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Polycystic Kidney, Autosomal Dominant; Primary Cell Culture; Triazoles; TRPP Cation Channels | 2014 |
Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Deferoxamine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Oropharyngeal Neoplasms; Papillomaviridae; Triazoles | 2014 |
UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Glucuronosyltransferase; HSP90 Heat-Shock Proteins; Humans; Triazoles | 2014 |
HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Colorectal Neoplasms; Down-Regulation; Drug Synergism; Female; Fluorouracil; HCT116 Cells; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; RNA, Small Interfering; Thymidylate Synthase; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2014 |
Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Mice, Nude; Molecular Targeted Therapy; Radiation Tolerance; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Triazoles; Xenograft Model Antitumor Assays | 2015 |
HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo.
Topics: Animals; B-Lymphocytes; Benzoquinones; Cytokines; HSP90 Heat-Shock Proteins; Inflammation; Killer Cells, Natural; Lactams, Macrocyclic; Lipopolysaccharides; Lung; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neutrophils; Triazoles | 2015 |
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Proto-Oncogene Proteins c-akt; Triazoles | 2015 |
The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.
Topics: Animals; B-Lymphocytes; Cyclophosphamide; Cytokines; Disease Models, Animal; Disease Progression; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Spleen; T-Lymphocytes; Triazoles | 2015 |
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Topics: Alleles; Allografts; Animals; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Female; Histone Deacetylase 6; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Lymphoma; Male; Mice; Molecular Targeted Therapy; Mutant Proteins; Neoplasm Transplantation; Protein Stability; Survival Rate; Tamoxifen; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
Topics: Benzofurans; Cell Cycle Proteins; Chaperonins; Drug Evaluation, Preclinical; Dyrk Kinases; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Luciferases; Molecular Chaperones; Mutation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Small Molecule Libraries; Thiazolidines; Triazoles | 2015 |
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Mice, Inbred ICR; Mice, SCID; Microscopy, Fluorescence; Molecular Targeted Therapy; Neoplasms; Resorcinols; Topoisomerase I Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Phenotype; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; Time Factors; Triazoles | 2015 |
Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Benzoquinones; Binding Sites; DNA-Binding Proteins; GTP-Binding Proteins; Heat Shock Transcription Factors; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lactams, Macrocyclic; Molecular Sequence Data; Mutation; Protein Binding; Protein Conformation; Protein Isoforms; Protein Kinase Inhibitors; Receptor, ErbB-2; Transcription Factors; Triazoles; Tumor Suppressor Proteins | 2015 |
Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Muscles; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Purine Nucleosides; Retinoblastoma Protein; Signal Transduction; Triazoles; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2015 |
Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; HSP90 Heat-Shock Proteins; Humans; Janus Kinase 2; JNK Mitogen-Activated Protein Kinases; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transfection; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Paclitaxel; Receptors, Glucocorticoid; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Ganetespib radiosensitization for liver cancer therapy.
Topics: Cell Proliferation; Humans; Liver Neoplasms; Radiation-Sensitizing Agents; Signal Transduction; Triazoles | 2016 |
Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
Topics: A549 Cells; Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoradiotherapy; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Radiation-Sensitizing Agents; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.
Topics: Animals; B-Lymphocytes; Cell Line, Transformed; Cell Survival; Cells, Cultured; Disease Models, Animal; Epstein-Barr Virus Infections; Epstein-Barr Virus Nuclear Antigens; Female; Herpesvirus 4, Human; HSC70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lymphocyte Count; Mice; Mice, SCID; T-Lymphocytes; Triazoles | 2017 |
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; DNA Damage; DNA Fragmentation; DNA Helicases; Drug Therapy, Combination; Fanconi Anemia Complementation Group A Protein; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Mitosis; Ovarian Neoplasms; Transplantation, Heterologous; Triazoles; Tripartite Motif-Containing Protein 28; Tumor Suppressor Protein p53 | 2017 |
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Auranofin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computer Simulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Transcription Factors; Triazoles | 2017 |
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Benzodioxoles; Benzoquinones; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Amplification; Genetic Predisposition to Disease; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mutation; Mutation, Missense; Neoplasms; Phenotype; Proto-Oncogene Proteins p21(ras); Purines; RNA Interference; Transfection; Triazoles | 2017 |
Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bridged-Ring Compounds; Case-Control Studies; Cell Movement; Cell Transformation, Neoplastic; Hemangiosarcoma; HSP90 Heat-Shock Proteins; Humans; Signal Transduction; Skin Neoplasms; Taxoids; Triazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2017 |
Combination Therapy of NSCLC Using Hsp90 Inhibitor and Doxorubicin Carrying Functional Nanoceria.
Topics: A549 Cells; Acrylic Resins; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cerium; Combined Modality Therapy; Doxorubicin; Drug Carriers; Folic Acid; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Nanoparticles; Rats; Reactive Oxygen Species; Triazoles | 2017 |
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Mammary Neoplasms, Experimental; Mice, SCID; Poly(ADP-ribose) Polymerase Inhibitors; Rad51 Recombinase; Radiation, Ionizing; Triazoles; Tumor Burden | 2017 |
Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.
Topics: Antineoplastic Agents; Benzamides; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Histones; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Isoindoles; Isoxazoles; Protein Processing, Post-Translational; Proteomics; Resorcinols; Triazoles; Urinary Bladder Neoplasms | 2017 |
Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclophosphamide; Disease Models, Animal; Drug Synergism; HSP90 Heat-Shock Proteins; Lymphoma; Mice; Triazoles; Tumor Suppressor Protein p53 | 2017 |
Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; HSP90 Heat-Shock Proteins; Humans; Mice, Nude; Signal Transduction; Thyroid Neoplasms; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Mice, Inbred BALB C; Mice, Nude; MutL Protein Homolog 1; Osteonectin; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling.
Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Signal Transduction; Stomach Neoplasms; Triazoles; Xenograft Model Antitumor Assays | 2017 |
DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain.
Topics: Catalytic Domain; Cell Cycle Proteins; Chaperonins; Dyrk Kinases; HeLa Cells; Humans; Metabolic Syndrome; Mutation; Phosphorylation; Protein Conformation; Protein Domains; Protein Folding; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Triazoles; Tyrosine | 2017 |
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.
Topics: Animals; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunotherapy; Interferons; Ipilimumab; Kaplan-Meier Estimate; Melanoma; Mice, Inbred C57BL; T-Lymphocytes; Triazoles; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cellular Senescence; Cisplatin; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Inbred NOD; Mice, SCID; Pemetrexed; Secretory Pathway; Triazoles | 2018 |
Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).
Topics: Animals; Aurora Kinase A; Cilia; Disease Models, Animal; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Knockout; NIMA-Related Kinases; Polycystic Kidney, Autosomal Dominant; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Triazoles | 2018 |
The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG.
Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Benzoquinones; Biological Products; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; MAP Kinase Signaling System; MCF-7 Cells; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase C; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2018 |
HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC.
Topics: Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cytoprotection; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Stability; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Domains; Triazoles; Up-Regulation | 2018 |
A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy.
Topics: Animals; Breast Neoplasms; Cell Line; Cell Line, Tumor; Drug Delivery Systems; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Indoles; Isoindoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Reactive Oxygen Species; Triazoles; Zinc Compounds | 2018 |
HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Cells, Cultured; Cholangiocarcinoma; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Microtubule-Associated Proteins; Phenylurea Compounds; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Triazoles | 2019 |
Inhibition of HSP90β by ganetespib blocks the microglial signalling of evoked pro-inflammatory responses to heat shock.
Topics: Animals; Cell Line, Transformed; Heat-Shock Response; HSP90 Heat-Shock Proteins; Inflammation; MAP Kinase Signaling System; Mice; Microglia; STAT3 Transcription Factor; Triazoles | 2019 |
Hsp90β inhibitors prevent GLT-1 degradation but have no beneficial efficacy on absence epilepsy.
Topics: Animals; Anticonvulsants; Benzoquinones; Epilepsy, Absence; Excitatory Amino Acid Transporter 2; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Hippocampus; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Mice; Pentylenetetrazole; Triazoles | 2019 |
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Genotype; High-Throughput Screening Assays; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Male; Mice; Phenotype; Phosphatidylinositol 3-Kinases; Prostate; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Radiosynthesis, biological evaluation and preliminary microPET study of
Topics: Animals; Binding Sites; Cell Line, Tumor; Click Chemistry; Crystallography, X-Ray; Drug Stability; Fluorine Radioisotopes; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Molecular Docking Simulation; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Transplantation, Heterologous; Triazoles | 2018 |
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Interleukin-6; Janus Kinase 2; Signal Transduction; Small Molecule Libraries; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus.
Topics: Animals; Antifungal Agents; Candida albicans; Cell Line; Drug Resistance, Fungal; Fungal Proteins; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Mice; Models, Molecular; Molecular Chaperones; Protein Binding; Protein Conformation; Protein Domains; Recombinant Proteins; Resorcinols; Signal Transduction; Triazoles; Virulence | 2019 |
177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Female; HSP90 Heat-Shock Proteins; Humans; Lutetium; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Triazoles; Tumor Cells, Cultured | 2019 |
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Triazoles | 2019 |
Nanomedicine-Assisted Combination Therapy of NSCLC: New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; CHO Cells; Cricetulus; Humans; Lung Neoplasms; Magnetic Fields; Magnetite Nanoparticles; Nanomedicine; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); Triazoles | 2019 |
Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Signal Transduction; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
HSP90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N
Topics: 5' Untranslated Regions; Adenosine; Cell Line, Tumor; Genes, Reporter; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Methylation; Proteomics; RNA, Messenger; Triazoles | 2019 |
High-Throughput Targeted Quantitative Analysis of the Interaction between HSP90 and Kinases.
Topics: HEK293 Cells; High-Throughput Screening Assays; HSP90 Heat-Shock Proteins; Humans; Protein Binding; Protein Kinases; Proteome; Proteomics; Triazoles | 2019 |
Hepatic Microwave Ablation-Induced Tumor Destruction and Animal End Point Survival Can Be Improved by Suppression of Heat Shock Protein 90.
Topics: Ablation Techniques; Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; HSP90 Heat-Shock Proteins; Liver Neoplasms, Experimental; Mice; Mice, Nude; Microwaves; Survival; Treatment Outcome; Triazoles | 2020 |
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Platinum; Proteomics; Triazoles; Xenograft Model Antitumor Assays | 2021 |
Heat shock protein 90 as a molecular target for therapy in oral squamous cell carcinoma: Inhibitory effects of 17‑DMAG and ganetespib on tumor cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Molecular Targeted Therapy; Mouth Mucosa; Mouth Neoplasms; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Triazoles | 2021 |
The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer.
Topics: Animals; Breast Neoplasms; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Triazoles | 2021 |
Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Osteosarcoma; Triazoles | 2021 |
Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cerium; CHO Cells; Combined Modality Therapy; Cricetinae; Cricetulus; Glycolipids; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Triazoles | 2021 |
Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Benzamides; Benzoquinones; Carcinoma, Pancreatic Ductal; Cell Culture Techniques, Three Dimensional; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Isoxazoles; Lactams, Macrocyclic; Molecular Structure; Pancreatic Neoplasms; Resorcinols; Rifabutin; Triazoles | 2021 |
Evolution of kinase polypharmacology across HSP90 drug discovery.
Topics: Binding Sites; Discoidin Domain Receptor 1; Drug Discovery; Evolution, Molecular; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Resorcinols; Triazoles | 2021 |
HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Repair; DNA Replication; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2021 |
Ganetespib selectively sensitizes cancer cells for proximal and distal spread-out Bragg peak proton irradiation.
Topics: Dose-Response Relationship, Radiation; Humans; Neoplasms; Protons; Relative Biological Effectiveness; Triazoles | 2022 |